Entheon Biomedical stock analysis
Entheon Biomedical (1XU) Stock Price & Analysis
1XU Stock Chart & Stats
- Day’s Range
- EUR 0.03 - EUR 0.03
- 52-Week Range
- EUR 0.02 - EUR 0.10
- Previous Close
- EUR 0.03
- Volume
- N/A
- Average Volume (3M)
- 25
- Market Cap
- EUR 440.55K
- Enterprise Value
- EUR 1.06M
- Total Cash (Recent Filing)
- EUR 321.83K
- Total Debt (Recent Filing)
- EUR 0
- Price to Earnings (P/E)
- ―
- Beta
- -0.78
- Next Earnings
- Mar 30, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance Sheet
The absence of reported debt limits interest obligations and reduces refinancing pressure while the company funds development activities. This gives management more flexibility than a leveraged biotechnology peer, although the benefit is tempered by recurring losses and a small capital base.
Focused Therapeutic Development
A focused research strategy can concentrate scarce resources on a defined unmet-need area rather than spreading investment across unrelated programs. Work on DMT-based candidates and supporting clinical and regulatory activities provides a coherent pathway toward potential medical applications.
Improved Cash Burn Versus Earlier Years
The improvement from the extreme cash-burn levels of 2021–2022 indicates some progress in controlling cash consumption over the broader period. If maintained, better cash discipline could extend the funding runway, though recent deterioration means this remains an uneven strength.
Bears Say
No Recent Revenue
Zero recent revenue shows that the company has not yet converted its research activities into a commercial income stream. Without recurring sales, progress depends on advancing candidates toward medical use, making future operating performance highly dependent on development execution.
Persistent Operating Losses
Recurring operating and net losses indicate that the current business model has not reached sustainable profitability. Continued losses reduce retained capital and leave limited evidence of self-funded growth, increasing the importance of successful development milestones and disciplined spending.
Ongoing Cash Funding Requirement
Persistent negative operating and free cash flow means the company continues to consume cash rather than generate it internally. That can constrain research progress or require additional external funding, while repeated financing needs may pressure financial flexibility if losses continue.
Entheon Biomedical News
1XU FAQ
What was Entheon Biomedical’s price range in the past 12 months?
What is Entheon Biomedical’s market cap?
When is Entheon Biomedical’s upcoming earnings report date?
How were Entheon Biomedical’s earnings last quarter?
Is Entheon Biomedical overvalued?
Does Entheon Biomedical pay dividends?
What is Entheon Biomedical’s EPS estimate?
How many shares outstanding does Entheon Biomedical have?
What happened to Entheon Biomedical’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Entheon Biomedical?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Entheon Biomedical
Entheon Biomedical Corp. operates as a biotechnology research and drug development company. It engages in developing and commercializing various N,N-dimethyltryptamine based psychedelic therapeutic products for treating addiction and substance use disorders. The company serves physicians, clinics, and licensed psychiatrists in Canada, the United States, and European Union. Entheon Biomedical Corp. is headquartered in Vancouver, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Timothy Ko
- Employees
- 1
- Website
- www.entheonbiomedical.com
- Address
- 999 West Broadway, Vancouver, BC, V5Z 1K5, CA
Entheon Biomedical (1XU) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 0 | 5 |
| Technical Analysis | 4 | 0 | 2 |
| Moving Averages | 9 | 0 | 3 |









